


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177 and Bond code: 40150)

REDEMPTION OF THE BONDS

This announcement is made by the board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 37.48(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Reference is made to the announcements of the Company dated 23 January 2020 and 17 February 2020 (the “**Announcements**”) in relation to the issue of EURO750,000,000 zero coupon convertible bonds due 2025 (the “**Bonds**”) by the Company. Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

Pursuant to the terms and conditions of the Bonds, on 17 February 2023, the holder of each Bond will have the right at such holder’s option, to require the Company to redeem all or some only of the Bonds of such holder on that date at their principal amount. The Company announces that on 17 January 2023, Optional Put Exercise Notices have been served on the paying agent of Company requesting the Company to redeem a principal amount of EURO487,582,000 in aggregate of the Bonds (“**Redeemed Bonds**”), representing approximately 99.6% of the outstanding principal amount of the Bonds as at the date of this announcement. Immediately after the completion of the redemption of the Redeemed Bonds, the principal amount of the Bonds remains outstanding will be EURO2,150,000.

The aforesaid redemption amount will be satisfied by internal resources of the Company. The Group maintains a strong liquidity position, with the Group’s cash and bank balances amounted to more than approximately RMB11 billion (unaudited; subject to audit and other adjustments; and excluding bank deposits classified under non-current assets and wealth management products) as of 31 December 2022, which are sufficient to meet all funding requirements in relation to the redemption of the Redeemed Bonds.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 19 January 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.